271 related articles for article (PubMed ID: 29991580)
1. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
[No Abstract] [Full Text] [Related]
2. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer.
Konings IC; Harinck F; Poley JW; Aalfs CM; van Rens A; Krak NC; Wagner A; Nio CY; Sijmons RH; van Dullemen HM; Vleggaar FP; Ausems MG; Fockens P; van Hooft JE; Bruno MJ;
Pancreas; 2017 Jan; 46(1):28-34. PubMed ID: 27846136
[TBL] [Abstract][Full Text] [Related]
3. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.
Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA
Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
5. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer.
Ibrahim IS; Bonsing BA; Swijnenburg RJ; Welling L; Veenendaal RA; Wasser MN; Morreau H; Inderson A; Vasen HF
Fam Cancer; 2017 Jan; 16(1):111-115. PubMed ID: 27406244
[TBL] [Abstract][Full Text] [Related]
6. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
7. Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers.
Ibrahim IS; Brückner C; Carrato A; Earl J; Inderson A; de Vos Tot Nederveen Cappel WH; Mintziras I; Matthäi E; Figiel J; Wasser M; Moreau H; Bonsing B; Slater EP; Bartsch DK; Vasen HF
United European Gastroenterol J; 2019 Jun; 7(5):682-688. PubMed ID: 31210946
[TBL] [Abstract][Full Text] [Related]
8. Variation in precursor lesions of pancreatic cancer among high-risk groups.
Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ;
Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Cancer Surveillance in Carriers of a Germline
Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME
J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.
Ibrahim IS; Vasen HFA; Wasser MNJM; Feshtali S; Bonsing BA; Morreau H; Inderson A; de Vos Tot Nederveen Cappel WH; van den Hout WB
United European Gastroenterol J; 2023 Mar; 11(2):163-170. PubMed ID: 36785917
[TBL] [Abstract][Full Text] [Related]
11. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
[TBL] [Abstract][Full Text] [Related]
12. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
Cao CX; Sharib JM; Blanco AM; Goldberg D; Bracci P; Mukhtar RA; Esserman LJ; Kirkwood KS
J Am Coll Surg; 2020 Jan; 230(1):53-63.e1. PubMed ID: 31672679
[TBL] [Abstract][Full Text] [Related]
13. Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program.
Vasen HFA; Boekestijn B; Ibrahim IS; Inderson A; Bonsing BA; de Vos Tot Nederveen Cappel WH; Feshtali S; Wasser MN
HPB (Oxford); 2019 Oct; 21(10):1371-1375. PubMed ID: 30910317
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.
Vasen HF; Wasser M; van Mil A; Tollenaar RA; Konstantinovski M; Gruis NA; Bergman W; Hes FJ; Hommes DW; Offerhaus GJ; Morreau H; Bonsing BA; de Vos tot Nederveen Cappel WH
Gastroenterology; 2011 Mar; 140(3):850-6. PubMed ID: 21129377
[TBL] [Abstract][Full Text] [Related]
15. Surveillance for pancreatic cancer in high-risk individuals.
Konings ICAW; Canto MI; Almario JA; Harinck F; Saxena P; Lucas AL; Kastrinos F; Whitcomb DC; Brand RE; Lachter J; Malleo G; Paiella S; Syngal S; Saltzman JR; Stoffel EM; van Hooft JE; Hruban RH; Poley JW; Fockens P; Goggins MG; Bruno MJ;
BJS Open; 2019 Oct; 3(5):656-665. PubMed ID: 31592073
[TBL] [Abstract][Full Text] [Related]
16. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer.
Del Chiaro M; Verbeke CS; Kartalis N; Pozzi Mucelli R; Gustafsson P; Hansson J; Haas SL; Segersvärd R; Andren-Sandberg Å; Löhr JM
JAMA Surg; 2015 Jun; 150(6):512-8. PubMed ID: 25853369
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
[TBL] [Abstract][Full Text] [Related]
18. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals.
Harinck F; Konings IC; Kluijt I; Poley JW; van Hooft JE; van Dullemen HM; Nio CY; Krak NC; Hermans JJ; Aalfs CM; Wagner A; Sijmons RH; Biermann K; van Eijck CH; Gouma DJ; Dijkgraaf MG; Fockens P; Bruno MJ;
Gut; 2016 Sep; 65(9):1505-13. PubMed ID: 25986944
[TBL] [Abstract][Full Text] [Related]
19. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance.
Kluijt I; Cats A; Fockens P; Nio Y; Gouma DJ; Bruno MJ
J Clin Gastroenterol; 2009 Oct; 43(9):853-7. PubMed ID: 19417680
[TBL] [Abstract][Full Text] [Related]
20. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
